Pages that link to "Q38454580"
Jump to navigation
Jump to search
The following pages link to Methylphenidate bioavailability from two extended-release formulations (Q38454580):
Displaying 26 items.
- Evolution of stimulants to treat ADHD: transdermal methylphenidate (Q22252903) (← links)
- Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data (Q24805432) (← links)
- Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges (Q26822392) (← links)
- Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate (Q33976616) (← links)
- Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers. (Q34719368) (← links)
- Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies. (Q35001357) (← links)
- Methylphenidate Efficacy: Immediate versus Extended Release at Short Term in Mexican Children with ADHD Assessed by Conners Scale and EEG. (Q35206892) (← links)
- An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety (Q35233563) (← links)
- Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin ® LA) in school children under daily practice conditions (Q35666257) (← links)
- Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications (Q35833310) (← links)
- Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults (Q36159334) (← links)
- Review and comparison of the long acting methylphenidate preparations (Q36218475) (← links)
- Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline (Q36471058) (← links)
- Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder (Q36622139) (← links)
- Metrics for the evaluation of bioequivalence of modified-release formulations (Q38036550) (← links)
- The clinical impact of switching attention deficit hyperactivity disorder patients from OROS(®)-MPH to Novo-MPH ER-C(®): A paediatric practice review. (Q38178250) (← links)
- Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder. A growth mixture modelling analysis (Q38439304) (← links)
- Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings (Q38566560) (← links)
- Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults (Q38953668) (← links)
- Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults (Q44369362) (← links)
- Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis (Q45022631) (← links)
- Recent advances in the treatment of narcolepsy (Q48293539) (← links)
- Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder (Q51899584) (← links)
- Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis (Q83308348) (← links)
- Pharmaceutical equivalence by design for generic drugs: modified-release products (Q83567967) (← links)
- Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteers (Q85663405) (← links)